Conflicts of Interest policy – New York Times

Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…

Go Slow on Mental Health Screening: Dr. Effrem Responds to New Freedom Commission Chair

Go Slow on Mental Health Screening: Dr. Karen Effrem responds to New Freedom Commission Chair, Michael Hogan – Wash Times Sun, 31 Oct 2004 A letter to the editor in the Washington Times – Go slow on Mental Health Screening – by AHRP’s newest board member, pediatrician Dr. Karen Effrem,…

Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times

Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…

Take Action: Just Say No to Stigmatizing Screening and Unsafe Drugs

Take Action: Just Say No to Stigmatizing Screening and Unsafe Drugs Tue, 26 Oct 2004 FYI /ACTION! AHRP believes that America’s school children should not be screened and labeled without a guarantee of the proven accuracy of the screening tool, and the proven safety and therapeutic value of the treatment…

Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug

Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…

Screening for Mental Illness–A Diabolical, Profit-Enhancing Experiment

Screening for Mental Illness–A Diabolical, Profit-Enhancing Experiment Fri, 22 Oct 2004 Concerned citizen groups are joining our effort to stop the government from implementing a sweeping recommendation for lifetime screening for mental illness. If implemented, the first to be screened for hidden mental illness are America’s 52 million school children…

Featured News

AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…

Failed Drug Treatments for Schizophrenia–Letters to the Editor – NYT

Failed Drug Treatments for Schizophrenia–Letters to the Editor – NYT Fri, 23 Sep 2005 Letters to the NY Times editor (below) demonstrate the combative reaction of stakeholders in the psychotropic drug industry to the evidence-based overthrow of psychiatry’s treatment recommendations. Psychiatrists who have financial contracts with psychotropic drug manfuacturers, have…

Infomail Archive 2005

Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…